[{"address1": "Wagistrasse 14", "city": "Schlieren", "zip": "8952", "country": "Switzerland", "phone": "41 44 755 77 00", "fax": "41 44 755 77 07", "website": "https://www.molecularpartners.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.", "fullTimeEmployees": 167, "companyOfficers": [{"maxAge": 1, "name": "Dr. Patrick  Amstutz Ph.D.", "age": 48, "title": "Co-Founder, CEO, Member of Management Board & Director", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 786456, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael Tobias Stumpp Ph.D.", "age": 51, "title": "Co-Founder, Executive VP of Projects & Member of Management Board", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Hendriks", "title": "Senior VP of Finance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Zurcher", "age": 48, "title": "COO & Member of Management Board", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Renate  Gloggner", "age": 53, "title": "Executive VP of People & Community and Member of Management Board", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Steiner Ph.D.", "title": "Senior Vice President of Research & Technology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Seth D. Lewis", "title": "Senior Vice President of Investor Relations, Communications & Strategy", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Pitzner", "title": "General Counsel, Compliance Officer, Senior VP Legal & Business Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Pamela A. Trail Ph.D.", "age": 67, "title": "Strategic Consultant", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anne  Goubier D.V.M., Ph.D.", "title": "Senior Vice President of Research & Early Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.77, "open": 6.0535, "dayLow": 5.7773, "dayHigh": 6.24, "regularMarketPreviousClose": 5.77, "regularMarketOpen": 6.0535, "regularMarketDayLow": 5.7773, "regularMarketDayHigh": 6.24, "beta": 0.614, "forwardPE": -3.3368983, "volume": 10453, "regularMarketVolume": 10453, "averageVolume": 16090, "averageVolume10days": 17200, "averageDailyVolume10Day": 17200, "marketCap": 236597696, "fiftyTwoWeekLow": 3.32, "fiftyTwoWeekHigh": 12.7, "priceToSalesTrailing12Months": 39.41981, "fiftyDayAverage": 5.41282, "twoHundredDayAverage": 5.12481, "currency": "USD", "enterpriseValue": 66259792, "floatShares": 6441303, "sharesOutstanding": 36837000, "sharesShort": 33492, "sharesShortPriorMonth": 29892, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.001, "heldPercentInstitutions": 0.053400002, "shortRatio": 4.5, "shortPercentOfFloat": 0.0015, "bookValue": 4.181, "priceToBook": 1.4924657, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -62591000, "trailingEps": -2.37, "forwardEps": -1.87, "enterpriseToRevenue": 11.04, "enterpriseToEbitda": -1.066, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "MOLN", "underlyingSymbol": "MOLN", "shortName": "Molecular Partners AG", "longName": "Molecular Partners AG", "firstTradeDateEpochUtc": 1623850200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "3b1227e2-09aa-3330-8282-b0e2c7493dad", "gmtOffSetMilliseconds": -18000000, "currentPrice": 6.24, "targetHighPrice": 17.08, "targetLowPrice": 10.05, "targetMeanPrice": 13.56, "targetMedianPrice": 13.56, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 143618000, "totalCashPerShare": 4.327, "ebitda": -62162000, "totalDebt": 2747000, "quickRatio": 14.081, "currentRatio": 14.33, "totalRevenue": 6002000, "debtToEquity": 1.979, "revenuePerShare": 0.182, "returnOnAssets": -0.21174, "returnOnEquity": -0.37369, "freeCashflow": -38458248, "operatingCashflow": -62041000, "revenueGrowth": -0.732, "operatingMargins": -21.42291, "financialCurrency": "CHF", "trailingPegRatio": null, "__fetch_time": "2024-11-07"}]